New York, Sep 26 (SocialNews.XYZ) A leading Covid-19 vaccine candidate developed by global healthcare company Johnson & Johnson produced a strong immune response against novel coronavirus in early-to-mid stage clinical trials, a report said.
According to the CNN, early results from a Phase 1/2a clinical trial show that it was well tolerated and even one dose appeared to produce a strong immune response in almost all of the 800 participants.
The trial included two age groups: 18-55 and 65 and above and looked at the safety and side-effects of two different doses.
Initial findings from the trials suggest that the vaccine does provoke an immune response and is safe enough to move into large-scale trials.
During the study, the researchers found that 99 per cent of the participants (age 18-55) in both dose groups developed antibodies against the virus 29 days after getting vaccinated.
The analysis found that most of the side-effects, like fever, headache, fatigue, body ache and injection-site pain, were mild and got resolved after a couple of days.
Some of the participants will be receiving a second shot of the vaccine as part of the trials. The vaccine -- called Ad26.COV2.S -- uses the same technology used for Johnson & Johnson's Ebola, Zika, HIV and RSV vaccines.
According to the report, Phase 3 trials will examine the safety and effectiveness of a single dose against a placebo to prevent symptomatic Covid-19.
Johnson & Johnson said it plans to enrol 60,000 adult volunteers at more than 200 sites in the US and internationally.
"The fact that the trials will examine the efficacy of a single dose of the vaccine, instead of two doses, should expedite results," Paul Stoffels, Johnson & Johnson's chief scientific officer, was quoted as saying by the CNN.
So far, it's the only Phase 3 Covid-19 vaccine trial in the US that is testing a single-dose of the vaccine.
Source: IANS
About Gopi
Gopi Adusumilli is a Programmer. He is the editor of SocialNews.XYZ and President of AGK Fire Inc.
He enjoys designing websites, developing mobile applications and publishing news articles on current events from various authenticated news sources.
When it comes to writing he likes to write about current world politics and Indian Movies. His future plans include developing SocialNews.XYZ into a News website that has no bias or judgment towards any.
He can be reached at gopi@socialnews.xyz